[From gene to disease; dopamine-beta-hydroxylase deficiency and orthostatic hypotension]

Area of Science:

• Genetics and Molecular Biology
• Neuroscience
• Pharmacology

Context:

• The DBH gene encodes dopamine-beta-hydroxylase (DbetaH), crucial for norepinephrine synthesis.
• Mutations in the DBH gene can lead to DbetaH deficiency, impacting the sympathetic nervous system.
• This deficiency results in a rare condition characterized by selective adrenergic failure.

Purpose:

• To describe the genetic basis and clinical manifestations of DBH gene mutations causing DbetaH deficiency.
• To highlight diagnostic criteria, distinguishing true deficiency from common polymorphisms.
• To present a therapeutic approach for this rare disorder.

Summary:

• DBH gene mutations cause dopamine-beta-hydroxylase (DbetaH) deficiency, leading to sympathetic nervous system adrenergic failure.
• Clinical presentation includes severe orthostatic syndrome with preserved sweating and parasympathetic function.
• Diagnosis relies on clinical signs and biochemical evidence (elevated dopamine, low norepinephrine), differentiating from non-pathogenic DbetaH absence.
• Treatment involves L-dihydroxyphenylserine, a precursor converted to norepinephrine.

Impact:

• Identifies a rare genetic disorder affecting catecholamine synthesis and autonomic function.
• Clarifies diagnostic challenges and provides a basis for accurate diagnosis.
• Offers a targeted therapeutic strategy for patients with DbetaH deficiency.